These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25775521)

  • 1. Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs.
    Jacques V; Czarnik AW; Judge TM; Van der Ploeg LH; DeWitt SH
    Proc Natl Acad Sci U S A; 2015 Mar; 112(12):E1471-9. PubMed ID: 25775521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deuterium-Enabled Chiral Switching (DECS) Yields Chirally Pure Drugs from Chemically Interconverting Racemates.
    DeWitt S; Czarnik AW; Jacques V
    ACS Med Chem Lett; 2020 Oct; 11(10):1789-1792. PubMed ID: 33062153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chiral inversion of the second generation IMiD CC-4047 (ACTIMID ) in human plasma and phosphate-buffered saline.
    Teo SK; Chen Y; Muller GW; Chen RS; Thomas SD; Stirling DI; Chandula RS
    Chirality; 2003 May; 15(4):348-51. PubMed ID: 12666243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Chung F; Palmer BD; Muller GW; Man HW; Kestell P; Baguley BC; Ching LM
    Oncol Res; 2003; 14(2):75-82. PubMed ID: 14649541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of thalidomide.
    Eriksson T; Björkman S; Höglund P
    Eur J Clin Pharmacol; 2001 Aug; 57(5):365-76. PubMed ID: 11599654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
    Ng SS; MacPherson GR; Gütschow M; Eger K; Figg WD
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4192-7. PubMed ID: 15217957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chiral discrimination between thalidomide enantiomers using a solid surface with two-dimensional chirality.
    Nakanishi T; Yamakawa N; Asahi T; Shibata N; Ohtani B; Osaka T
    Chirality; 2004; 16 Suppl():S36-9. PubMed ID: 15239071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues.
    Wnendt S; Finkam M; Winter W; Ossig J; Raabe G; Zwingenberger K
    Chirality; 1996; 8(5):390-6. PubMed ID: 8900028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others.
    Tokunaga E; Akiyama H; Soloshonok VA; Inoue Y; Hara H; Shibata N
    PLoS One; 2017; 12(8):e0182152. PubMed ID: 28763493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enantiomerization mechanism of thalidomide and the role of water and hydroxide ions.
    Tian C; Xiu P; Meng Y; Zhao W; Wang Z; Zhou R
    Chemistry; 2012 Nov; 18(45):14305-13. PubMed ID: 23065668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide.
    Eriksson T; Björkman S; Roth B; Fyge A; Höglund P
    Chirality; 1995; 7(1):44-52. PubMed ID: 7702998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
    Bodera P; Stankiewicz W
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):192-6. PubMed ID: 21913886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The enantiomers of the teratogenic thalidomide analogue EM 12: 1. Chiral inversion and plasma pharmacokinetics in the marmoset monkey.
    Schmahl HJ; Nau H; Neubert D
    Arch Toxicol; 1988; 62(2-3):200-4. PubMed ID: 3143339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the Thalidomide Chirality in Biological Processes by the Self-disproportionation of Enantiomers.
    Tokunaga E; Yamamoto T; Ito E; Shibata N
    Sci Rep; 2018 Nov; 8(1):17131. PubMed ID: 30459439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man.
    Eriksson T; Björkman S; Roth B; Höglund P
    J Pharm Pharmacol; 2000 Jul; 52(7):807-17. PubMed ID: 10933131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide analogs as emerging anti-cancer drugs.
    Dredge K; Dalgleish AG; Marriott JB
    Anticancer Drugs; 2003 Jun; 14(5):331-5. PubMed ID: 12782937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CC-5013 (Celgene).
    Mitsiades CS; Mitsiades N
    Curr Opin Investig Drugs; 2004 Jun; 5(6):635-47. PubMed ID: 15242253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production.
    Marriott JB; Westby M; Cookson S; Guckian M; Goodbourn S; Muller G; Shire MG; Stirling D; Dalgleish AG
    J Immunol; 1998 Oct; 161(8):4236-43. PubMed ID: 9780198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chiral switch: pure enantiomers of drugs instead of racemic mixtures].
    Valentová J; Hutt AJ
    Ceska Slov Farm; 2004 Nov; 53(6):285-93. PubMed ID: 15630994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supramolecular dynamics of thalidomide and its derivatives in water-sediment system.
    Ali I; Gupta VK; Aboul-Enein HY
    Chirality; 2010 May; 22(4):416-24. PubMed ID: 19618419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.